Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Investor Presentation November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Jefferies Healthcare Conference Presentation – June 2019
Press Releases
ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019
press release
November 4, 2019
Geneva, Switzerland and Boston, MA –November 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical…
Read moreObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
press release
October 31, 2019
FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV…
Read moreObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
press release
October 11, 2019
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Christophe Lamps
Dynamics Group
+41 79 476 26 87
Media United States
Marion Janic
RooneyPartners LLC
+1 212-223-4017
Contacts
Sign up for news
